Literature DB >> 12576319

ADAMTS13 gene mutation in congenital thrombotic thrombocytopenic purpura with previously reported normal VWF cleaving protease activity.

Sureyya Savasan1, Soon-Ki Lee, David Ginsburg, Han-Mou Tsai.   

Abstract

Deficiency of von Willebrand factor (VWF) cleaving protease ADAMTS13 is associated with the development of thrombotic thrombocytopenic purpura (TTP). A case of congenital TTP that was previously reported to have normal ADAMTS13 activity was analyzed at the molecular level. Reanalysis of plasma VWF cleaving protease activity using a different assay revealed that the patient had less than 0.1 U/L ADAMTS13 protease activity, while the parents were both partially deficient. Sequence analysis of DNA amplified by polymerase chain reaction showed that the patient was homozygous for a novel TT deletion in exon 15 of the ADAMTS13 gene resulting in a frameshift, while both parents were heterozygous for the same mutation. Taken together with other recent reports, all the cases of hereditary TTP studied by DNA sequence analysis to date appear to be due to mutations within the ADAMTS13 gene.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12576319     DOI: 10.1182/blood-2002-12-3796

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  13 in total

Review 1.  ADAMTS13 and microvascular thrombosis.

Authors:  Han-Mou Tsai
Journal:  Expert Rev Cardiovasc Ther       Date:  2006-11

2.  Enzymatically active ADAMTS13 variants are not inhibited by anti-ADAMTS13 autoantibodies: a novel therapeutic strategy?

Authors:  Wenhua Zhou; Lingli Dong; David Ginsburg; Eric E Bouhassira; Han-Mou Tsai
Journal:  J Biol Chem       Date:  2005-10-03       Impact factor: 5.157

3.  Why Do We Need ADAMTS13?

Authors:  Han-Mou Tsai
Journal:  Nihon Kessen Shiketsu Gakkai shi       Date:  2005

4.  Recombinant CUB-1 domain polypeptide inhibits the cleavage of ULVWF strings by ADAMTS13 under flow conditions.

Authors:  Zhenyin Tao; Yuandong Peng; Leticia Nolasco; Santiago Cal; Carlos Lopez-Otin; Renhao Li; Joel L Moake; José A López; Jing-Fei Dong
Journal:  Blood       Date:  2005-09-01       Impact factor: 22.113

Review 5.  The molecular biology of thrombotic microangiopathy.

Authors:  H-M Tsai
Journal:  Kidney Int       Date:  2006-05-31       Impact factor: 10.612

Review 6.  Molecular biology of ADAMTS13 and diagnostic utility of ADAMTS13 proteolytic activity and inhibitor assays.

Authors:  Suresh G Shelat; Jihui Ai; X Long Zheng
Journal:  Semin Thromb Hemost       Date:  2005-12       Impact factor: 4.180

Review 7.  Pathophysiology of thrombotic thrombocytopenic purpura.

Authors:  Han-Mou Tsai
Journal:  Int J Hematol       Date:  2010-01       Impact factor: 2.490

Review 8.  The kidney in thrombotic thrombocytopenic purpura.

Authors:  H-M Tsai
Journal:  Minerva Med       Date:  2007-12       Impact factor: 4.806

Review 9.  Thrombotic thrombocytopenic purpura related to severe ADAMTS13 deficiency in children.

Authors:  Chantal Loirat; Jean-Pierre Girma; Céline Desconclois; Paul Coppo; Agnès Veyradier
Journal:  Pediatr Nephrol       Date:  2008-06-24       Impact factor: 3.714

Review 10.  Pathogenesis of thrombotic microangiopathies.

Authors:  X Long Zheng; J Evan Sadler
Journal:  Annu Rev Pathol       Date:  2008       Impact factor: 23.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.